VICTORIA, BRITISH COLUMBIA--(Marketwire - Oct. 18, 2010) - Following today's trading halt by Investment Industry Regulatory Organization of Canada, CardioComm Solutions, Inc. (TSX VENTURE:EKG) (the "Company") today confirmed that there is no material information pertaining to the Company which has not been disclosed.
About CardioComm Solutions, Inc.
CardioComm Solutions, Inc. ("CardioComm") has been a consistent provider of ECG management software solutions in the English speaking world for the past 21 years. Its products are marketed as Global ECG Management System (GEMS™) and GlobalCardio™. CardioComm is ISO 13485 certified and its products have been cleared for sale in the United States, Canada and the European Union. CardioComm's competitive advantage is built upon 2 ECG patents, a unique FDA approved ECG analysis algorithm, a world class ECG (signal) viewer and a back-end ECG data management control system. CardioComm's technology enables the recording, transfer, viewing, analyzing, reporting and storing of electrocardiograms (EKGs) over a global virtual healthcare network by physicians for the diagnosis and management of cardiac patients. CardioComm provides an ECG management solution which complements the majority of the world's cardiac event monitors, including those intended for the home and tele-health market. CardioComm products are sold worldwide to hospitals, call centers and physicians offices through a combination of its external distribution network and its North American based sales team.
On behalf of the Board of Directors of CardioComm Solutions, Inc.
Anatoly Langer, Chairman of the Board
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.